The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
We want to inform you about an important update regarding T-Spot test collections and deliveries. Due to severe weather conditions expected to affect parts of the United States, we have been advised by our reference laboratory to suspend the collection and sending of this test on Monday, February 17 after 3 p.m. through Tuesday, February 18. Testing collection will begin again on Wednesday, February 19th, unless the request is extended.
This precaution is necessary to ensure the safety and integrity of the specimens, as well as to avoid any potential delays or issues that could arise from the adverse weather. We appreciate your understanding and cooperation during this time.
If your patient is experiencing symptoms and requires a Covid test, please choose one of the options below:
Collect the specimen in your office and send the specimen to any Corewell Health Laboratory or with your Corewell Health Courier, if available.
• Please be sure to place a collected order in Epic or your EMR, or include a paper order with the specimen.
• Please make sure the specimen is labeled with 2 patient identifiers, date and time of collection, and source (nasopharyngeal or nares)
For all other options please visit: Corewell Health COVID-19 screening and testing
NOTE: Walk-in COVID-19 testing is not available at any of our sites, including emergency departments, urgent care locations or walk-in clinics. Testing is available to registered patients who are seeking medical treatment.
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
Chromosome Analysis Prenatal and Chromosome Analysis Prenatal Limited orders will now include cryopreservation of prenatal specimens (amniotic fluid and chorionic villi), excluding those found to have straightforward abnormalities (i.e. whole chromosome copy gain).
TEST INFORMATION
Effective Wednesday, January 1, 2025, the in-house test, Research Creatine Kinase MB Fraction (CK-MB) (LAB2111534) will be made inactive. Recommended alternative testing is CK-MB (CK-2) (TC:17581) which is referred to Quest Diagnostics.
For questions or additional information, please use the Contact Us link above.
The following information was updated in the Lab Catalog.
All changes are for Corewell Health West Laboratories. For East and South locations, please visit: corewellhealth.org/labcatalog
On Tuesday, Jan. 7, you will see changes to the ABN Status list in Epic, making it easier to select the appropriate status from available options.
In an effort to optimize workflows, the ABN statuses in Epic have been changed to be more efficient. Some statuses have been removed based on volume of use and feedback from clinicians. Other options have been changed to ensure clarity after review by Informatics, Compliance, and Revenue Cycle. The information below lists the new options and when to use them. Please refer to Epic Proportions for more information.
Attention providers: to reduce your ABN workflow burden, please select one of the first two Provider ABN statuses at the time of order entry only. The collection of signed ABN waivers will occur later by office, laboratory, or imaging staff using the three ABN Signed statuses when the specimen is being collected or when the imaging procedure is being performed. If your office routinely collects laboratory specimens, please instruct your staff to collect ABN signature waiver at the time of specimen collection.
Status Options Available after January 7, 2025:
Effective January 8, 2025, a new version of Beta CTX-1 (Cross Laps) will be implemented with the discontinuation of the previous version.
The analytical measuring range and reference ranges will be updated with the new version of the test. It is recommended to not directly compare the results between the new and old version of the test. If assistance is needed to aid in trending results between the new and old version of the test, please use the contact us link above or contact the Corewell Health Reference Laboratory West, Immunochemistry Department.
TEST INFORMATION
Influenza prevalence fluctuates seasonally, and case numbers are currently increasing throughout West Michigan. The onset of “flu season” varies year-to-year though typically begins its upswing in the month of December. It is important for providers to have an awareness of influenza prevalence (in addition to other respiratory viruses) to help guide when influenza testing should be pursued.
The use of point of care (POC) antigen testing reduces both the cost to the patient and turn-around-time as compared to lab-based molecular methods. POC antigen tests are typically available for COVID-19, influenza A/B, and as a COVID-19/influenza A/B combination test. During warmer months when influenza prevalence is negligible yet COVID-19 may be circulating, a COVID-only antigen test may be helpful for diagnosis. As influenza increases into colder months, a COVID-19/Influenza A/B combo test would act as a screen for both viruses.
POC tests generally have high analytical specificity but lack the sensitivity of nucleic acid amplification methods (e.g. PCR). For this reason, PCR testing is still recommended for hospitalized patients and for outpatients with a negative POC result if influenza is still suspected and if the result will impact clinical decision making. Influenza PCR may be ordered as a standalone test (LAB3255) or as a part of a panel alongside COVID-19 and RSV (LAB1230746).
Local Infection Prevention Team
Michigan Department of Health and Human Services